Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Nov 01 2006

Related Content

IP vs. Know-How: in RNAi, the Battle Is Joined

Feb 01 2003

RNAi Revs Up

Oct 01 2002

RNAi Enters the Clinic for Macular Degeneration

Dec 01 2004

The Large Molecule Future

Jun 01 2006

Moving Beyond Accutane and Botox

Nov 01 2006

Novartis Opens Door to Broad Dealmaking in RNAi

Oct 01 2005

Related Companies

Sirna Therapeutics

Merck & Co., Inc.

Alnylam Pharmaceuticals Inc.

Merck & Co., Inc.

Novartis AG

Medarex

Amgen, Inc.

Genentech, Inc.

Allergan plc

Opko Health

Vertex Pharmaceuticals Incorporated

InterMune, Inc.

Medtronic plc

GSK plc

Pfizer Inc.

AstraZeneca PLC

Roche Holding AG

Additional Topics

Strategy Business Strategies Clinical Trials Innovation BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window